TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Internet- Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder in a Psychiatric Setting: A Randomized Equivalence Trial
Brief Summary: Panic Disorder with or without agoraphobia (PD/A) is a common, and unless it is treated, often chronic psychiatric disorder. The are effective pharmacological as well as psychological treatments for PD/A. Because of the lack of availability of the most effective psychological treatment, cognitive behavior therapy (CBT), self-help based CBT treatments have been developed. One of those are Internet-based CBT. The aim of this study is to compare the effectiveness of Internet and group CBT for PD/A in a regular psychiatric setting. 113 patients are consecutively and randomly assigned to either treatment (both lasting 10 weeks). The main outcome measure is the Panic Disorder Severity Scale(PDSS). The study hypothesis is that treatments will show equal effectiveness.


Options:
A: Inclusion Criteria:

* Must have a primary diagnosis of social phobia

Exclusion Criteria:

* Substance abuse during the last 6 months
* Other dominating diagnosis (not phobic personality disorder)
* A history of bipolar disorder or psychosis
* Major depression according to DSM-IV and \>20 on madrs-s
* Risk of suicide
* Start of medication or change of dosis during the last 2 months
* Other parallel psychological treatment
* Previous CBT (last 3 years) for social phobia
B: Inclusion Criteria:

* Be between the ages of 18-30 years old or 31-46 years old
* Have reoccurring panic attacks

Exclusion Criteria:

* Suicide prone
* Alcohol addiction
* PTSD
* OCD
* Ongoing psychological treatment
C: Inclusion Criteria:

* Primary Panic Disorder with or without Agoraphobia (PD/A)

Exclusion Criteria:

* active substance abuse
* physiological etiology of panic symptoms
* under 18 years of age
* severe depression or suicidal ideation.
* if on drugs for PD, not having had a constant dosage for 2 months
* undergoing other cognitive behavioral treatment
D: Inclusion Criteria:

* Primary diagnosis of hypochondriasis
* At least 18 years old
* Able to read and write in swedish
* Computer access

Exclusion Criteria:

* Drug abuse
* Concurrent severe depression
* No serious somatic illness
* Previous treatment with CBT for hypochondriasis

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Local Injury to Endometrium on the Day of Oocyte Retrieval in First IVF Cycle on Implantation Rate.
Brief Summary: Local injury on two sights of endometrium are performed in 60 patients in their first IVF cycle and implantation rate are compared with fresh cycles without local injury.


Options:
A: Inclusion Criteria:

* women aged between 20 and 39 years with at least one year of infertility
* regular menstruation with the length of the cycle between 22-34 days and ovulation confirmed by appropriately timed mid-luteal progesterone
* fertile semen variables
* bilateral tubal patency (demonstrated by laparoscopy or hysterosalpingography).
B: Inclusion Criteria:

* women with recurrent implantation failure which was defined as 2-6 cycles unsuccessful of IVF-ET in which more than 10 high grade embryo were transferred

Exclusion Criteria:

* age over than 40 years old
* poor responders to ovarian stimulation
C: Inclusion Criteria:

* Age \< 35
* First IVF cycle
* Long protocol should be used for stimulation

Exclusion Criteria:

* Day 3 FSH \> 10
D: Inclusion Criteria:

* Women who will start assisted reproductive techniques with planned fresh embryo transfer.
* Age between 18 and 38 years.
* Written informed consent.

Exclusion Criteria:

* None

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Local Injury to Endometrium on the Day of Oocyte Retrieval in First IVF Cycle on Implantation Rate.
Brief Summary: Local injury on two sights of endometrium are performed in 60 patients in their first IVF cycle and implantation rate are compared with fresh cycles without local injury.


Options:
A: Inclusion Criteria:

* All patients medically cleared to do a fresh or frozen embryo transfer.
* Age up to 42 years

Exclusion Criteria:

* microsurgical epididymal sperm aspiration (MESA) and Testicular sperm extraction (TESE) patients
* At least one partner carrier of a chromosomal or genetic disease
* Abnormal ovarian reserve, defined as follicle stimulating hormone (FSH) of \>10 IU/L on day 2-4 of the cycle and anti-mullerian hormone (AMH) \< 1ng /ml (If only one of the two parameters altered then patients is acceptable). This is based on Mandy Katz abstract at American Society for Reproductive Medicine (ASRM) 2011 where they showed that these patients have 35% chance of having no euploid embryos - They are excluded only to make the study size smaller, otherwise, if an euploid embryo is found in these patients, they implant as well as patients with normal ovarian reserve. Not all centers do AMH testing - we recommend first to run FSH and only test AMH if FSH is abnormal.
* Egg donor cycle (sperm donor is acceptable)
* Gender selection cycles
* Thaw cycles
B: Inclusion Criteria:

* Age of female partner \< 43 y/o AMH \< 1.1 OR BAFC \< 8 (within previous year) Male must have \>100,000 motile sperm BMI \< 32

Exclusion Criteria:

* Diagnosis of endometrial insufficiency Use of oocyte donor/gestational carriers Use of surgical sperm or DNA Banking Communicating hydosalpinges (HSG) Single gene disorders or sex selection Participation in another study
C: Inclusion Criteria:

* Scheduled to undergo in vitro fertilization for treatment of infertility (1st or 2nd "fresh" attempt); subject can have had no more than one prior failed "fresh" IVF cycle
* Couple able to participate in a research project

  * Able to understand study requirements
  * Willing to sign informed consent
  * Able to return for required follow-up
  * Access to telephone
  * Ability to read and write
* Normal uterine cavity evaluation within one year of enrollment

Exclusion Criteria:

* Medical conditions which may complicate treatment
* No plans to undergo embryo transfer
* Medical contraindication to the transfer of more than a single embryo (i.e. congenital uterine anomaly).
* Concurrent participation in any other interventional trial
* Recurrent pregnancy loss
* Known chromosomal abnormality (e.g. translocation)
* Pre-implantation genetic diagnosis requiring blastocyst biopsy
D: Inclusion Criteria:

* Age \< 35
* First IVF cycle
* Long protocol should be used for stimulation

Exclusion Criteria:

* Day 3 FSH \> 10

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Local Injury to Endometrium on the Day of Oocyte Retrieval in First IVF Cycle on Implantation Rate.
Brief Summary: Local injury on two sights of endometrium are performed in 60 patients in their first IVF cycle and implantation rate are compared with fresh cycles without local injury.


Options:
A: Inclusion Criteria:

* Women with history of primary or secondary infertility undergoing fresh IVF/ ICSI treatment or frozen embryo replacement cycle
* Age \<49

Exclusion Criteria:

* Non- ovulatory cycles
* Absent uterus
* Uterine instrumentation within previous 3 menstrual cycles
* Women in the oocyte donation program
B: Inclusion Criteria:

* Women who will start assisted reproductive techniques with planned fresh embryo transfer.
* Age between 18 and 38 years.
* Written informed consent.

Exclusion Criteria:

* None
C: Inclusion Criteria:

* Age \< 35
* First IVF cycle
* Long protocol should be used for stimulation

Exclusion Criteria:

* Day 3 FSH \> 10
D: Inclusion Criteria:

* Age \< 43 years
* Normal uterine cavity shown on ultrasound scanning

Exclusion Criteria:

* Age \>=43
* Three previous IVF cycles
* Use of donor oocytes
* Natural IVF or IVM cycles
* Abnormal uterine cavity on ultrasound scanning
* ET canceled because of absent fertilization or risk of ovarian hyperstimulation syndrome
* Blastocyst transfer
* Undergoing preimplantation genetic diagnosis
* Recruited in the same study before

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Open-label, Cross-over Study Comparing Two Vitamin D Supplements for Infants: Liquid Versus D-Strips.
Brief Summary: Vitamin D supplementation (400 IU/d) is recommended for all breastfed infants in Canada. Such recommendation is grounded in the fact that the prevalence of rickets in Canada is higher than desirable, likely due to low maternal-fetal transfer and low intakes postpartum.

There is little data about adherence to supplementation in Canada, but one study shows that in primiparous mothers (n=1937) in Quebec, 58.1 % of those exclusively breast-feeding gave their infant vitamin D supplements in the first six months and 62.1 % of those feeding formula did not. For the Canadian situation, it is not clear if the modality of the supplementation is a barrier to providing the supplement. Thus the overall aim of this study is to test a new delivery system for parental preference and infant acceptance compared to a standard vitamin D supplement.


Options:
A: Inclusion Criteria:

1. Healthy children by parental report
2. Have reached their 1st birthday but not past their 6th birthday
3. Present to a TARGet Kids! practice for routine primary healthcare prior to viral season (September through November)
4. Parents provide informed consent to participate.

Exclusion Criteria:

1. Children with gestational age \< 32 weeks
2. Children with chronic illness (except for asthma) on parental report which is known to interfere with vitamin D metabolism and increase the risk of respiratory infection
3. Children with a sibling participating in the study to reduce clustering effects.
B: Inclusion Criteria:

* Clinical features of rickets
* Active rickets on X-ray

Exclusion Criteria:

* Treatment with calcium or vitamin D in preceding 30 days
C: Inclusion Criteria:

* Healthy singleton newborn infants born at term age of any racial background.
* Infants may be breastfed or formula fed during the study as is safe since the supplement is 400 IU/d and intakes from breast milk or formula will not exceed 400 IU/d for a theoretical total intake of 800 IU/d that is recommended by the Canadian Pediatric Society.

Exclusion Criteria:

* Infants born prematurely, twins or other multiples.
* Unable to nurse or accept the supplement.
* Congenital malformations.
* Parents not fluent enough in English or French to provide written informed consent.
D: Inclusion Criteria:

* Healthy mothers \> 18 years of age
* Term, healthy infants eligible to receive the Bacille-Calmette- Guerin (BCG) vaccine

Exclusion Criteria:

* Recent maternal history of tuberculosis (within 1 year) or active tuberculosis
* Known maternal human immuno-deficiency virus (HIV) infection
* Maternal fever or chorio-amnionitis
* Maternal use of vitamin D, steroids or immuno-regulatory medications
* Household member with active tuberculosis

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Collaborative Care Program to Improve Depression Treatment in Cardiac Patients
Brief Summary: Depression in cardiac patients is common, persistent, and deadly. However, the vast majority of cardiac patients with depression go unrecognized and untreated, despite the existence of treatments that clearly improve depressive symptoms and may favorably impact survival. Our research group and others have found that depression recognition and treatment appears particularly limited among patients with acute cardiac illness, though this population may be the most vulnerable to the deleterious effects of depression. We propose a project, building on successful collaborative care depression management programs in outpatient settings, to address this important issue.

The specific hypotheses behind the proposed research are that a collaborative care depression management program can be successfully adapted to inpatient cardiac units, and that such a program will lead to greater rates of adequate depression treatment and improvements in secondary outcomes.

The following specific aims capture the stepwise goals of this program:

1. To determine whether a collaborative care depression management program ('Enhanced Care') leads to significantly increased rates of adequate depression treatment compared to usual care (screening and feedback) (Primary Aim).
2. To assess whether this Enhanced Care program has a lasting impact on adequate depression treatment, depressive symptoms, health-related quality of life, and adherence to medical recommendations at 6 weeks, 12 weeks, and 6 months, compared to usual care.


Options:
A: Inclusion Criteria:

* Inpatient admission for cardiac diagnosis
* Positive depression evaluation (PHQ-2\>2, PHQ-9\>9)
* Ability to provide informed consent

Exclusion Criteria:

* Active suicidal ideation
* Bipolar disorder, psychotic disorder, active substance use disorder
B: Inclusion Criteria:

* Meets criteria for major depression based on a score of greater than 2 for five or more symptoms, including one of the two cardinal depression symptoms and a nine-item depression scale of the Patient Health Questionnaire (PHQ-9) score of greater than 10
* Patient with diabetes
* Has attended two community safety net clinics

Exclusion Criteria:

* Current suicidal ideation
* Score of 8 or greater on the Alcohol Use Disorders Identification Test (AUDIT)
* Recent use of lithium or antipsychotic medication
C: Inclusion Criteria:

* Alzheimers Disease

Exclusion Criteria:

* Inability to understand English
* No telephone
D: Inclusion Criteria:

* Patients currently receiving primary care at Portland VAMC
* Diagnosed musculoskeletal chronic pain condition lasting at least 3 months
* Currently experiencing moderate to severe symptoms as per screening
* Willingness to complete 6 and 12 month interviews
* Regular access to a telephone

Exclusion Criteria:

* Dementia or cognitive disturbance
* Diagnoses of fibromyalgia, chronic fatigue or somatization disorder Terminal illness
* Designated guardian
* Drug-seeking behavior flag in medical record

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double-Masked Clinical Trial of Phacoemulsification Compared With Phacoemulsification and Micro-Bypass Stent Implantation in Patients With POAG
Brief Summary: This was a prospective, double-masked, 15-month clinical trial comparing efficacy of phacoemulsification alone to combined phacoemulsification and implantation of the iStent® trabecular micro-bypass stent in patients with primary open-angle glaucoma.


Options:
A: Inclusion Criteria:

* Phakic study eye
* IOP ≥ 21 mmHg and ≤ 40 mmHg at screening exam (OHT requires second screening)

Exclusion Criteria:

* Aphakic or pseudophakic eyes (AC-IOLs or PC-IOLs)
* Previous usage of topical prostaglandin analogues or prior medical therapy for glaucoma
B: Inclusion Criteria:

* a previous diagnosis of POAG
* an IOP of \> 18 mm Hg at three separate visits if on one medication, or subjects on at least two medications with uncontrolled IOP on three separate visits.
* all patients were deemed likely to follow surgeon instructions and were able to give informed consent.

Exclusion Criteria:

* any glaucoma diagnosis other than POAG
* the presence of peripheral anterior synechiae (PAS)
* a cloudy cornea likely to inhibit gonioscopic view of the angle
* any previous ocular surgery
* history of trauma or ocular surface disease
* the presence of peripheral anterior synechiae (PAS)
* a cloudy cornea likely to inhibit gonioscopic view of the angle
C: Inclusion Criteria:

* Diagnosed with open-angle glaucoma (OAG) in the study eye. Pseudoexfoliative and pigmentary glaucoma are also acceptable diagnoses.
* Subject on at least one glaucoma medication
* Able and willing to attend follow up visits for two years post operative
* Able and willing to sign informed consent

Exclusion Criteria:

* Prior glaucoma procedures (eg trabeculectomy, viscocanalostomy, ALT, SLT, shunt implant, collagen implant, cyclo destructive procedures etc)
* Angle closure glaucoma
* Fellow eye already enrolled
D: Inclusion Criteria:

* Newly diagnosed with open-angle glaucoma (OAG) or Ocular Hypertension with subjects not yet taking any glaucoma medications or recently diagnosed with mild open-angle glaucoma and are currently being treated with up to 2 glaucoma medications.
* All subjects must need cataract surgery.

Exclusion Criteria:

* Angle closure glaucoma
* Secondary glaucomas except pseudoexfoliative and pigmentary; no neovascular, uveitic or angle recession glaucoma
* Prior glaucoma procedures (eg trabeculectomy, viscocanalostomy, ALT, SLT, shunt implant, collagen implant, cyclo destructive procedures etc)
* Fellow eye already enrolled

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Brief Summary: This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.


Options:
A: Inclusion Criteria:

* Have a diagnosis of rheumatoid arthritis (RA) (according to the revised 1987 criteria of the ACR) for at least 3 months prior to first administration of study agent
* Are methotrexate (MTX)-naïve (ie, have not received more than 3 weekly doses of MTX for RA at any time)
* Have active RA as defined by persistent disease activity with at least 4 swollen and 4 tender joints, at the time of screening and baseline, and at least 2 of the following 4 criteria: a) C-reactive protein (CRP) \>=1.5 mg/dL at screening or erythrocyte sedimentation rate (ESR) by Westergren method of \>= 28 mm in the first hour at screening or baseline, b)Morning stiffness of \>= 30 minutes at screening and baseline, c)Bone erosion by x-ray and/or MRI prior to first administration of study agent, d)Anti-cyclic citrullinated peptide (anti-CCP) antibody-positive or rheumatoid factor (RF) positive at screening
* If using oral corticosteroids, must be on a stable dose equivalent to \<= 10 mg of prednisone/day for at least 2 weeks prior to first administration of study agent.

Exclusion Criteria:

* Can not have inflammatory diseases other than RA that might confound the evaluation of the benefit of golimumab therapy
* No treatment with disease-modifying anti-rheumatic drugs (DMARDs)/systemic immunosuppressives during the 4 weeks prior to the first administration of study agent
* No prior treatment with biologic anti-TNF drugs (infliximab, etanercept, adalimumab)
* No history of, or ongoing, chronic or recurrent infectious disease
* No serious infection within 2 months prior to first administration of study agent.
B: Inclusion Criteria:

* Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate

Exclusion Criteria:

* Pregnancy, severe acute or chronic medical conditions, including serious infections or clinically significant laboratory abnormalities.
C: Inclusion Criteria:

* male/female, 18-75 years old, inclusive
* diagnosis of adult-onset RA
* had active disease
* had received methotrexate
* on a stable dose of folic acid

Exclusion Criteria:

* contraindication for methotrexate or anti-TNF
D: Inclusion Criteria:

* Satisfies the 1987 ACR Revised Criteria for Rheumatoid Arthritis
* Has RA greater than or equal to 3 months and less than or equal to 2 years

Exclusion Criteria:

* Received any previous treatment with MTX
* Received any previous treatment with ETN or other tumour necrosis factor antagonist

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Intérêt d'Utiliser Des solutés de Remplissage équilibrés à la Phase précoce d'un Traumatisme crânien Grave Pour Limiter l'Acidose hyperchlorémique
Brief Summary: isotonic NaCl serum is the first intent solution for infusion during the initial phase of reanimation for an acute cranial traumatism.

However, its use can trigger an hyperchloremic metabolic acidosis, what could be deleterious for the future of this patient.

Isofundine present all charateristics to be use in this indication: pharmacokinetic and pharmacodynamic similar to the physiologic serum, iso-osmolarity to plasma, no glucose provision and no interaction with hemostasis.


Options:
A: Inclusion Criteria:

* Emergency department patient
* Chief complaint of nausea, vomiting or emesis, diarrhea, abdominal pain, dehydration, heat stroke or exhaustion
* ED provider approves administration of two liters of fluid
* ED provider states patient is likely to be discharged
* Patient has followed up with PCP in the last two years
* Patient has access to phone for next two days following ED discharge

Exclusion Criteria:

* Prisoners
* Children
* Women known to be pregnant
* Jaundice
* Current chemotherapy
B: Inclusion Criteria:

Adult patients present in the ICU on the study day or admitted during the 24-hour study period will be included in the study sample.

Exclusion Criteria:

Children under 16 years are excluded
C: Inclusion Criteria:

* All Intensive Care Unit (ICU) admissions at Austin Hospital
* All Emergency Department (ED) admissions at Austin Hospital
* All operations at Operating Theatre (OT) with hospital stay of more than 48 hours

Exclusion Criteria: Nil
D: Inclusion Criteria:

* Glasgow \< or equal to 8
* Patient \> 18 years old

Exclusion Criteria:

* Polytraumatism
* Pregnancy
* Patient under guardianship
* renal insufficiency, hypokaliemia, hypocalcemia

Answer: D